Valuation PharmaEssentia Corporation LUXEMBOURG S.E.
Stocks
261280558
US7169721047
Biotechnology & Medical Research
|
End-of-day quote
LUXEMBOURG S.E.
2026-10-16
|
5-day change | 1st Jan Change | ||
| 38.40 USD | +3.23% |
|
+2.67% | +184.16% |
Company Valuation: PharmaEssentia Corporation
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 78,065 | 143,840 | 114,578 | 204,725 | 173,829 | 486,957 | - | - |
| Change | - | 84.26% | -20.34% | 78.68% | -15.09% | 180.14% | - | - |
| Enterprise Value (EV) 1 | 75,148 | 133,629 | 94,995 | 183,725 | 153,423 | 463,909 | 452,715 | 486,957 |
| Change | - | 77.82% | -28.91% | 93.4% | -16.49% | 202.37% | -2.41% | 7.56% |
| P/E | -27.1x | -98.6x | -179x | 69.3x | 34.6x | 43.5x | 27.3x | - |
| PBR | 19.1x | 11.2x | 4.79x | 7.45x | 5.46x | 11x | 8.39x | - |
| PEG | - | 1.8x | 3x | -0x | 0.5x | 0x | 0.5x | - |
| Capitalization / Revenue | 119x | 49.9x | 22.4x | 21x | 11.1x | 17.9x | 11.7x | 8.39x |
| EV / Revenue | 114x | 46.4x | 18.6x | 18.9x | 9.81x | 17x | 10.9x | 8.39x |
| EV / EBITDA | -29x | -74.2x | -57.8x | 87.3x | 28.8x | 33.4x | 19.3x | 15.7x |
| EV / EBIT | -26.6x | -65.9x | -49.6x | 106x | 31.1x | 35.8x | 20.1x | 15.9x |
| EV / FCF | -29.7x | -73.5x | -49.8x | 102x | 41.7x | 65.8x | 44.3x | - |
| FCF Yield | -3.37% | -1.36% | -2.01% | 0.98% | 2.4% | 1.52% | 2.26% | - |
| Dividend per Share 2 | - | - | - | 0.8936 | 1.352 | 4 | 2.35 | - |
| Rate of return | - | - | - | 0.18% | 0.32% | 0.34% | 0.2% | - |
| EPS 2 | -8.773 | -3.932 | -1.568 | 7.214 | 12.25 | 27.03 | 43.02 | - |
| Distribution rate | - | - | - | 12.4% | 11% | 14.8% | 5.46% | - |
| Net sales 1 | 656.5 | 2,882 | 5,106 | 9,735 | 15,635 | 27,227 | 41,511 | 58,043 |
| EBITDA 1 | -2,595 | -1,800 | -1,645 | 2,104 | 5,327 | 13,907 | 23,451 | 30,942 |
| EBIT 1 | -2,822 | -2,028 | -1,913 | 1,736 | 4,928 | 12,946 | 22,538 | 30,594 |
| Net income 1 | -2,811 | -1,375 | -623.8 | 2,966 | 5,045 | 10,927 | 18,250 | - |
| Net Debt 1 | -2,917 | -10,211 | -19,582 | -21,000 | -20,406 | -23,048 | -34,242 | - |
| Reference price 2 | 238.02 | 387.49 | 281.07 | 499.59 | 423.70 | 1,175.00 | 1,175.00 | 1,175.00 |
| Nbr of stocks (in thousands) | 327,980 | 371,210 | 407,644 | 409,783 | 410,264 | 414,432 | - | - |
| Announcement Date | 3/2/22 | 3/1/23 | 2/27/24 | 2/26/25 | 3/3/26 | - | - | - |
1TWD in Million2TWD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 18.77x | 6.69x | 13.41x | 1.58% | 65B | |
| 35.3x | 6.27x | 18.74x | 0.92% | 51.2B | |
| 27.56x | 7.53x | 23.83x | 0.05% | 51.19B | |
| 34.01x | 3.32x | 14.33x | -.--% | 43.93B | |
| 48.9x | 5.59x | 30.73x | -.--% | 41.96B | |
| -18.47x | 189.62x | -19.51x | -.--% | 38.14B | |
| 28.97x | 8.21x | 21.25x | 0.37% | 33.24B | |
| 29.19x | 6.17x | 16.01x | -.--% | 25.2B | |
| 30.74x | 5.69x | 19.09x | -.--% | 22.5B | |
| Average | 26.11x | 26.57x | 15.32x | 0.32% | 41.37B | |
| Weighted average by Cap. | 25.97x | 25.01x | 15.48x | 0.44% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- 6446 Stock
- 261280558 Stock
- Valuation PharmaEssentia Corporation
Select your edition
All financial news and data tailored to specific country editions
